---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-013490"
form_type: "8-K"
ticker: "TTRX"
cik: "0002023016"
company_name: "Turn Therapeutics Inc."
filed_at: "2026-02-09T23:59:59+00:00"
generated_at: "2026-05-16T03:57:15.336105+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Turn Therapeutics announces presentations at TD Cowen and Oppenheimer healthcare conferences

## Summary
- CEO Brad Burnam to present at 46th Annual TD Cowen Healthcare Conference in Boston on March 2, 2026.
- Also presenting virtually at 36th Annual Oppenheimer Healthcare Life Sciences Conference on February 25, 2026.
- Company to provide update on Phase 2 trial of GX-03 for moderate-to-severe atopic dermatitis.
- Updated investor presentation posted on company website on February 9, 2026.

## SEC filing metadata
- accession: 0001213900-26-013490
- form_type: 8-K
- ticker: TTRX
- cik: 0002023016
- company_name: Turn Therapeutics Inc.
- filed_at: 2026-02-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2023016/000121390026013490/0001213900-26-013490-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2023016/000121390026013490/ea0275934-8k_turn.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-013490
- JSON: https://secwatch.observer/filing/0001213900-26-013490.json
- Plain text: https://secwatch.observer/filing/0001213900-26-013490.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.